MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Moexipril Hydrochloride And Hydrochlorothiazide, and when can generic versions of Moexipril Hydrochloride And Hydrochlorothiazide launch?
Moexipril Hydrochloride And Hydrochlorothiazide is a drug marketed by Chartwell Rx, Glenmark Pharms, Heritage, and Teva. and is included in four NDAs.
The generic ingredient in MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; moexipril hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; moexipril hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE?
- What are the global sales for MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE?
- What is Average Wholesale Price for MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE?
Summary for MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 4 |
US Patents and Regulatory Information for MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
Summary
Moexipril Hydrochloride and Hydrochlorothiazide combination represents a therapy designed for hypertension management. Investment prospects hinge on patent status, market demand, regulatory approvals, and manufacturing scalability. Fundamentals analysis underscores its competitive positioning, lifecycle stage, and potential market expansion.
What is the Market Position and Demand for Moexipril Hydrochloride and Hydrochlorothiazide?
This fixed-dose combination (FDC) targets patients with hypertension requiring multi-mechanistic therapy. Data from the Global Data Health Technology Assessment (2022) indicates the global antihypertensive drugs market was valued at approximately $30 billion, with ACE inhibitors like Moexipril constituting about 12%. Hydrochlorothiazide remains a widely used diuretic, essential in combination therapies.
The FDC market is expanding, driven by adherence benefits in polypharmacy. While Moexipril formulations are less prevalent than enalapril or lisinopril, partnerships and patent extensions could enhance lifecycle. The combination remains attractive in markets with limited drug access, especially via generics.
Patent and Regulatory Status
The original patents for Moexipril expired around 2010, but patent protection for specific formulations or combination devices can persist longer. Regulatory approval status varies across territories:
- United States: Approved as Moexipril tablets (FDA). The specific combination with Hydrochlorothiazide is sometimes approved as an unpatented, off-label combination.
- European Union: Marketing authorization granted for Moexipril; combination products require separate dossier submissions.
- Emerging markets: Often rely on generic formulations; patent litigation may influence market entry timing.
FDA or EMA approval processes for new fixed-dose combinations demand demonstration of bioequivalence, safety, and efficacy, adding time and cost. Patent obstacles and regulatory hurdles influence lifecycle and market exclusivity.
Competitive Landscape
Multiple ACE inhibitors and thiazide diuretics compete in the antihypertensive market:
| Drug Class | Key Drugs | Market Share (2022) | Notes |
|---|---|---|---|
| ACE inhibitors | Lisinopril, Enalapril, Moexipril | 50% (overall ACE) | Moexipril's market share <5%; limited compared to others |
| Thiazides | Hydrochlorothiazide (HCTZ) | Dominant diuretic | Widely available; low cost |
The combination's positioning is constrained by generic competition, patent expirations, and the presence of several approved alternatives.
Manufacturing and Supply Chain Analysis
Manufacturers with established facilities for ACE inhibitors and diuretics can scale production efficiently. Cost structures depend on the synthesis complexity of Moexipril, which involves multi-step chemical synthesis and purification processes. Hydrochlorothiazide is inexpensive and mass-produced.
Supply chain disruptions could impact pricing and availability, especially in emerging markets. Regulatory compliance and quality controls at manufacturing sites influence approval and market entry timelines.
Market Penetration and Growth Drivers
Growth hinges on multiple factors:
- Clinical Guidelines: Adoption in treatment protocols affects prescribing patterns.
- Patient Adherence: Fixed-dose combinations increase adherence, lowering long-term healthcare costs.
- Pricing Strategy: Generics lower drug prices; patent protections can command premium prices during exclusivity periods.
- Regulatory Bottlenecks: Longer approval timelines delay market access, affecting revenue streams.
International markets offer varying opportunities based on local healthcare infrastructure, patent laws, and disease prevalence.
Financial and Investment Considerations
For investors:
- Early-stage: Asset value depends on patent life, regulatory pathway progress, and licensing agreements.
- Mid-stage: Revenue potential aligns with market penetration, manufacturing capacity, and competitive response.
- Late-stage: Existing generic competition necessitates aggressive cost management and distinct positioning.
Licensures from patent holders or partnerships with established pharmaceutical companies can mitigate risks associated with entry and scale.
Key Challenges
- Patent expiration reduces exclusivity.
- Generic entrants offer lower prices, compressing margins.
- Regulatory costs and delays impact ROI timelines.
- Competition from established combination therapies limits market share growth.
Potential Upsides
- Strategic positioning in targeted markets with underserved populations.
- Expansion into combination therapy segments for resistant or complicated hypertension cases.
- Development of next-generation formulations with improved bioavailability or reduced side effects.
Key Takeaways
Investments in Moexipril Hydrochloride and Hydrochlorothiazide hinges on patent status, market demand, and regulatory environment. The drug faces generic competition, limiting pricing power, but sustained demand for antihypertensive therapy sustains its relevance. Scalability and market expansion opportunities depend on navigating patent landscapes, securing regulatory approvals, and forming strategic partnerships. Early-stage efforts should focus on lifecycle management and differentiation, while established players may leverage manufacturing efficiencies and regional access.
FAQs
More… ↓
